Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sercan Aksoy

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Breast (Edinburgh, Scotland)|October 8, 2022
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter studyHasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, et al.
Breast Cancer Research and Treatment|December 19, 2023
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCYJudith Balmaña, Peter A Fasching, Fergus J Couch, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|May 25, 2024
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)Arif Akyildiz, Deniz Can Guven, Baris Koksal, et al.
The Lancet. Oncology|April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.
Lancet (London, England)|April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trialFabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
International Journal of Clinical Oncology|February 4, 2024
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) studyHasan Çağrı Yıldırım, Yasin Kutlu, Emel Mutlu, et al.
Journal of Clinical Medicine|June 26, 2025
Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group StudySerhat Sekmek, Aysel Oguz, Melek Karakurt Eryilmaz, et al.
Immunotherapy|April 21, 2026
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumabAli Kaan Güren, Nazım Can Demircan, Özge Gümüşay, et al.
Frontiers in Immunology|December 26, 2025
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter studyTaha Koray Sahin, Fatih Atalah, Bahadir Koylu, et al.
Journal of Chemotherapy (Florence, Italy)|March 18, 2024
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) studyHasan Cagri Yildirim, Caner Kapar, Baris Koksal, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Breast (Edinburgh, Scotland)|October 8, 2022
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter studyHasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, et al.
Breast Cancer Research and Treatment|December 19, 2023
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCYJudith Balmaña, Peter A Fasching, Fergus J Couch, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|May 25, 2024
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)Arif Akyildiz, Deniz Can Guven, Baris Koksal, et al.
The Lancet. Oncology|April 1, 2024
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialJean-Pascal Machiels, Yungan Tao, Lisa Licitra, et al.
Lancet (London, England)|April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trialFabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
International Journal of Clinical Oncology|February 4, 2024
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) studyHasan Çağrı Yıldırım, Yasin Kutlu, Emel Mutlu, et al.
Journal of Clinical Medicine|June 26, 2025
Induction or Adjuvant Chemotherapy in Patients with Locally Advanced Nasopharyngeal Cancer Receiving Chemoradiotherapy? A Turkish Oncology Group StudySerhat Sekmek, Aysel Oguz, Melek Karakurt Eryilmaz, et al.
Immunotherapy|April 21, 2026
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumabAli Kaan Güren, Nazım Can Demircan, Özge Gümüşay, et al.
Frontiers in Immunology|December 26, 2025
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter studyTaha Koray Sahin, Fatih Atalah, Bahadir Koylu, et al.
Journal of Chemotherapy (Florence, Italy)|March 18, 2024
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) studyHasan Cagri Yildirim, Caner Kapar, Baris Koksal, et al.
Pageof 21